US President Donald Trump had a video removed from Twitter following a report of copyright infringement. We look at why brand misuse could increase significantly during the 2020 US presidential election.
Anonymous street artist Banksy has opened a pop-up shop in London in response to an ongoing trademark dispute with a card manufacturer. The attorney representing the card company reacts to the opening.
TGI Fridays trademark lead Leanne Stendell explains how she built an in-house trademark team from the ground up to meet the needs of a restaurant chain with over 50 years of goodwill.
New data reveals that 3,441 trademark litigation actions have been filed in the United States to date. The figures mean that 2019 is on course to represent a four-year high in filings.
In our latest round-up, we look at Huawei filing a lawsuit against a rival Chinese mobile maker, POW! Entertainment hitting back over Stan Lee lawsuit, Alt Legal acquiring MarkTend, and much more.
In 2018 the top development strategy of companies involved in the Russian pharmaceutical market was ‘aggressive marketing’. In such circumstances, trademark registration takes on considerable importance as it provides an effective measure to secure exclusive rights over a product’s unique identity.
Several pharmaceutical trademarks exist that have not yet been put to use, mostly as a result of licensing problems, and are therefore vulnerable to non-use defence. Any opposition on the basis of such kinds of trademark can be overcome by non-use defence.
Amendments to China’s Trademark Law are due to take effect on 1 November 2019. The changes should aid the authorities in their bid to crack down on malicious filings and trademark hoarding.
Recent developments in US federal law now permit the sale of cannabis-derived products under certain conditions in states where such products are also legal under state law. This will have implications for the selection and protection of pharmaceutical trademarks.
There is no clear link between the IP Law and the Health Law and their regulations regarding conflicts between registered trademarks and marketing authorisations or distinctive names.
In Romania, pharmaceutical trademarks are governed by the same national legislation and relevant EU directives and regulations as other trademarks. However, some specific elements must be taken into account.
There are no specific provisions relating to international non-proprietary names (INNs) in Saudi Arabia’s Trademark Law. As a member of the WHO, in practice Saudi Arabia implements the World Health Assembly resolution over INNs.
Given the highly profitable trade in pharmaceutical parallel imports where price differences and arbitrage opportunities arise from different national pricing regulations, it is anticipated that the issue of parallel imports will remain a significant area of concern for pharmaceutical companies.
World Trademark Review takes a deep dive into the top Asia-Pacific trademark offices and how they are modernising their systems to better protect applicants and streamline procedures. While this has positively affected filing levels, economic performance and domestic businesses will be key going forward.
Colour marks remain difficult to obtain, but brand owners can take certain steps to enhance their chances of success.